GB2092596A - Process for the production of human parathyroid hormone - Google Patents
Process for the production of human parathyroid hormone Download PDFInfo
- Publication number
- GB2092596A GB2092596A GB8138588A GB8138588A GB2092596A GB 2092596 A GB2092596 A GB 2092596A GB 8138588 A GB8138588 A GB 8138588A GB 8138588 A GB8138588 A GB 8138588A GB 2092596 A GB2092596 A GB 2092596A
- Authority
- GB
- United Kingdom
- Prior art keywords
- human
- cells
- hpth
- process according
- lymphoblastoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 title claims abstract description 11
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 title claims abstract description 11
- 102000058004 human PTH Human genes 0.000 title claims abstract description 11
- 241001465754 Metazoa Species 0.000 claims abstract description 28
- 229940088597 hormone Drugs 0.000 claims abstract description 10
- 239000005556 hormone Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 90
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 9
- 241000700159 Rattus Species 0.000 claims description 7
- 230000007910 cell fusion Effects 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- 206010033963 Parathyroid tumour Diseases 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 238000011580 nude mouse model Methods 0.000 claims description 6
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005296 lung carcinoma Diseases 0.000 claims description 5
- 241000699800 Cricetinae Species 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 102000016605 B-Cell Activating Factor Human genes 0.000 claims description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 241000283707 Capra Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000272201 Columbiformes Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 229940039009 isoproterenol Drugs 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 8
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000006285 cell suspension Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000036046 immunoreaction Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 201000010174 renal carcinoma Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000849 parathyroid Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A process for the production of human parathyroid hormone (hPTH), comprising in vivo multiplication of human lymphoblastoid cells capable of producing said hormone, using a non-human warm-blooded animal, and in vitro cultivation of the multiplied human lymphoblastoid cells to produce hPTH.
Description
SPECIFICATION
Process for the production of human parathyroid hormone
The present invention relates to a process for the production of human parathyroid hormone (abbreviated as hPTH hereinafter).
hPTH is a hormone, secreted by the parathyroid glands, that regulates the synthesis of activated vitamin D3, stimulates the release of calcium from bones and leads to an increase in the calcium level of the blood. No process for the mass production of low-cost hPTH has been established to date.
We have investigated processes for the mass production of hPTH and have unexpectedly found that certain human lymphoblastoid cells capable of producing hPTH are suitable for the mass production of hPTH owing to their very high multiplication efficiency and high rate of hPTH production per cell.
According to the present invention there is provided a process for the production of hPTH, which process comprises multiplying human lymphoblastoid cells capable of producing said hormone by transplanting said cells to a nonhuman warm-blooded animal body, or alternatively by allowing said cells to multiply within a device in which the nutrient body fluid of a non-human warm-blooded animal is supplied to said cells, and allowing the human lymphoblastoid cells multiplied by either of the above multiplication procedures to release said hormone.
The process according to the invention provides an extremely high hPTH yield, requires much less nutrient medium containing expensive serum for the cell multiplication or no such medium, and renders much easier the maintenance of the culture medium during the cell multiplication than in in vitro tissue culture. Particularly, any human lymphobiastoid cells capable of producing hPTH can be multiplied easily while utilising the nutrient body fluid supplied from the non-human warmblooded animal body by transplanting said cells to the animal body, or suspending the cells in a conventional diffusion chamber devised to receive the nutrient body fluid of the animal, and feeding the animal in the usual way. Also, in the present process one obtains a more stable and a higher rate of cell multiplication, and a higher hPTH production per cell.
As regards the human lymphoblastoid cells which may be used in the present invention, any human lymphoblastoid cells can be used as long as they produce hPTH and multiply rapidly in the non-human warm-blooded animal body.
Preferable human lymphoblastoid cells are those introduced with hPTH production governing genetic sites of human cells which inherently produce hPTH such as normal or transformed parathyroid cells, or human cells which produce ectopic hPTH such as lung carcinoma cells, ovarian tumor cells, kidney carcinoma cells or liver carcinoma cells by means of cell fusion using polyethylene glycol, or by genetic recombination techniques using DNA ligase, nuclease and DNA polymerase; and other human lymphoblastoid cells which produce ectopic hPTH. Since the use of such human lymphoblastoid cells results in the formation of easily disaggregatable massive tumors when the cells are transplanted to the animal body, and the massive tumors are barely contaminated with the host animal cells, the multiplied live human lymphoblastoid cells can be harvested easily.
Any non-human warm-blooded animal can be used to perform the process of the present invention as long as the human lymphoblastoid cells multiply therein. Examples of suitable animals are poultry such as chickens or pigeons, and mammals such as dogs, cats, monkeys, goats, pigs, cows, horses, guinea pigs, rats, hamsters, mice and nude mice. Since transplantation of the human lymphoblastoid cells gives rise to undesirable immunoreactions, the use of a newborn or infant animal, or of an animal in the youngest possible stage, for example, in the form of an egg, embryo or foetus, is desirable.In order to reduce the incidence of immunoreactions as much as possible, prior to the cell transplantation the animal may be treated with Xray of y-ray irradiation, at about 200-600 rem, or with an injection of antiserum or an immuncsuppressive agent prepared according to conventional methods. Nude mice exhibit weak immunoreactions; consequently, any human lymphoblastoid lines capable of producing hPTH can advantageously be transplanted into, and rapidly multiplied in, nude mice without subjecting the mice to a pretreatment for suppressing immunoreactions.
Stabilised cell multiplication and enhancement of hPth production can be both carried out by repeated transplantation using combination(s) of different non-human warm-blooded animals; the objectives are attainable first by implanting said cells in hamsters and multiplying the cells therein, then by reimplanting the cells in nude mice.
Repeated transplantation may be carried out with animals of the same class or division as well as those of the same species or genus.
The human cells to be multiplied can be implanted in any site of the animal as long as they multiply at that site; for example, in the allantoic cavity, or intraveneously, intraperitoneally, or subcutaneously.
In addition to the above-mentioned direct cell transplantation, any conventional human lymphoblastoid lines capable of producing hPTH can be multiplied easily by using the nutrient body fluid supplied from the animal body by embedding, for example, intraperitoneally, in the animal body a conventional diffusion chamber, of various shapes and sizes, and equipped with a porous membrane filter, ultra filter or hollow fiber having a pore size of about 10-7 to 10-5 m in diameter which prevents ingress of the host animal cells into the chamber but permits the cells to be supplied with the nutrient body fluid of the animal. Furthermore, the diffusion chamber can be designed, if desired, so as to enable observation of the cell suspension in the chamber through transparent side window(s) provided on the chamber wall(s), and so as to enable replacement and exchange with a fresh chamber.In this way cell production per host can be increased to even higher levels over the period of the animal's life without any sacrifice of the host animal. When such a diffusion chamber is used, since little immunoreaction arises owing to the absence of direct contact of the human cells with the host animal cells, the multiplied human lymphoblastoid cells can be harvested easily, and any non-human warm-blooded animal can be used as the host in the present process without the need for any pretreatment to reduce immunoreactions.
Feeding of the host animal can be carried out by conventional methods even after cell transplantation, and no special care is required.
Maximum cell multiplication can be attained within 1-20 weeks, generally 1-5 weeks, after the cell transplantation.
According to the invention, the number of the human lymphoblastoid cells obtained per host ranges from about 107 to 1012 or more. In other words, the number of the human lymphoblastoid cells implanted in the animal body increases about 102 to 107 times or more, or about 10' to 106 times or more than that attained by in vitro tissue culture method using a nutrient medium; the human lymphoblastoid cells can therefore be used advantageously in the production of hPTH.
As regards the method by which the human lymphoblastoid cells multiplied by either of the above described procedures are allowed to release hPTH, any methods can be employed as long as the said human cells release the desired hormone thereby. For example, human lymphoblastoid cells, obtained by multiplying in ascite in suspension and harvesting from said ascite, or by extracting the massive tumor formed subcutaneously and harvesting after the disaggregation of the massive tumor, are suspended to give a cell concentration of about 104 to 108 cells per ml in a nutrient medium, prewarmed at a temperature of about 20--400C, and then incubated at this temperature for about 1 to 100 hours to produce hPTH.During the incubation, enhancement of hPTH production may be carried out by including one or more of an amino acid such as glycine, leucine, lysine, arginine and cysteine; an inorganic salt such as sodium chloride, potassium chloride, calcium chloride and magnesium sulfate; and a hormone such as dopamine, isoproterenol, epinephrine and norepinephrine.
The hPTH thus obtained can be collected easily by purification and separation techniques using conventional procedures such as salting-out, dialysis, filtration, centrifugation, concentration and lyophilisation. If a more highly purified hPTH preparation is desirable, a preparation of the highest purity can be obtained by the abovementioned techniques in combination with other conventional procedures such as adsorption and desorption with ion exchange, gel filtration, affinity chromatography, isoelectric point fractionation and electrophoresis.
The hPTH preparation thus obtained can be used advantageously alone or in combination with one or more agents for injection, or for external, internal or diagnostical administration in the prevention and treatment of human diseases.
The following Examples illustrate the present invention.
In this specification, hPTH production was determined by a bioassay method as described in
J. A. Parsons et a/., Endocrinology, Vol 92, pp.
454-462 (1973), and is expressed by weight in terms of the standard hPTH preparation, assigned 1,300 USP units per mg, available from the
National Institute of Health (USA).
EXAMPLE 1
Disaggregated human parathyroid tumor cells - extracted from a patient suffering from parathyroid tumor and minced - and a human leukemic lymphoblastoid line Namalwa were suspended together in a vessel with a salt solution, containing 140 mM NaCI, 54 mM KCl, 1 mM NaH2PO4 and 2 mM CaCI2, to give a respective cell concentration of about 104 cells per ml. The ice-chilled cell suspension was mixed with a fresh preparation of the same salt solution containing UV-irradiation preinactivated Sendai virus, transferred into a 370C incubator five minutes after the mixing, and stirred therein for 30 minutes to effect cell fusion, thereby introducing the ability of the human parathyroid tumor cells of producing hPTH into the human leukemic lymphoblastoid line.
After cloning according to conventional methods the hybridoma cell strain capable of producing hPTH, the hybridoma cells strain was implanted intraperitoneally in adult nude mice which were then fed in the usual way for five weeks. The resulting massive tumors, about 1 5 g each, were extracted and disaggregated by mincing and trypsinizing.
After washing the cells with Earle's 1 99 medium (pH 7.2), supplemented with 10 v/v % foetal calf serum, the cells were resuspended to give a cell concentration of about 105 cells per ml in a fresh preparation of the same medium which contained 30 mM L-arginine and 20 mM CaCI2, and then incubated at 370C for 40 hours to produce hPTH. Thereafter, the cells were treated ultrasonically, and the hPTH in the resulting supernatant was determined. The hPTH production was about 830 ng per ml cell suspension.
Control cells were obtained by cultivating in vitro the human parathyroid cells at 370C in
Earle's 199 medium (pH 7.2), supplemented with 10 v/v % foetal calf serum. These cells were treated similarly as described above to produce hPTH. The hPTH production was only about 4 ng per ml cell suspension.
EXAMPLE 2
Disaggregated human kidney carcinoma cells -- extracted from a patient suffering from kidney carcinoma and minced - and a human leukemic lymphoblastoid line JBL were fused in a manner similar to that described in Example 1, thereby introducing the ability of the human kidney carcinoma cells of producing hPTH into the human leukemic lymphoblastoid line.
After cloning according to conventional methods the hybridoma cell strain capable of producing hPTH, the hybridoma cell strain was implanted subcutaneously in newborn hamsters which had been preinjected with an antiserum (prepared from rabbits using conventional methods) so as to reduce the immunoreactions of the rabbits. The rabbits were then fed in the usual way for three weeks.
The resulting massive tumors, formed subcutaneously and about 10 g each, were extracted and disaggregated by mincing and suspending in a physiological saline solution containing collagenase.
After washing the cells with Eagle's minimal essential medium (pH 7.4), supplemented with 5 v/v % human serum, the cells were resuspended to give a cell concentration of about 106 cells per ml in a fresh preparation of the same medium which contained 20 mM CaCI2 and 20 mM dopamine, and then incubated at 370C for 20 hours to produce hPTH. The hPTH production was about 1.3 g per ml cell suspension.
Control cells were obtained similarly as described in Example 1 by cultivating in vitro the fused human leukemic lymphoblastoid line JLB.
The control cells were treated similarly as described above. The hPTH production was only about 1 6 ng per ml cell suspension.
EXAMPLE 3
Newborn rats were implanted intravenously with a human leukemic lymphoblastoid line BALL-1 into which the ability of human ovarian tumor cells of producing hPTH had been introduced in a manner similar to that described in Example 1, and then fed in the usual way for four weeks.
The resulting massive tumors, about 30 g each, were extracted and treated similarly as described in Example 1 to produce hPTH. The hPTH production was about 900 ng per ml suspension.
Control cells were obtained similarly as described in Example 1 by cultivating in vitro the fused human leukemic lymphoblastoid line
BALL-1. These control cells were treated similarly as described above. The hPTH production was only about 10 ng per ml cell suspension.
EXAMPLE 4
After about 400 rem X-ray irradiation of adult mice to reduce their immunoreactions, the mice were implanted subcutaneously with a human leukemic lymphoblastoid line NALL-1 into which the ability of human lung carcinoma cells to produce hPTH had been introduced in a manner similar to that described in Example 1. The mice were then fed in the usual way for three weeks.
The resulting massive tumors, formed subcutaneously and about 1 5 g each, were extracted and treated similarly as described in
Example 2 to produce hPTH. The hPTH production was about 1.2 jug per ml cell suspension.
Control cells were obtained similarly as described in Example 1 by cultivating in vitro the fused human leukemic lymphoblastoid line
NALL-1. The control cells were treated similarly as described above. The hPTH production was only about 20 ng per ml cell suspension.
EXAMPLE 5
A human leukemic lymphoblastoid line TALL-1 into which the ability of the human parathyroid tumor cells to produce hPTH had been introduced in a manner similar to that described in Example 1 was suspended in physiological saline solution, and the resulting cell suspension was transferred into a plastic cylindrical diffusion chamber (inner volume: about 10 ml) and equipped with a membrane filter having a pore size of about 0.5 Su in diameter. After intraperitoneal embedding of the chamber into an adult rat, the rat was fed in the usual way for four weeks, and the chamber was removed.
The human lymphoblastoid cell density in the chamber attained by the above operation was about 6 x 108 cells per ml which was about 102 times higher or more than that attained by in vitro cultivation using a CO2 incubator. The human lymphoblastoid cells thus obtained were treated similarly as described in Example 2 to produce hPTH. The hPTH production was about 1.1 y9 per ml cell suspension.
Control cells were obtained by suspending the
human parathyroid tumor cells in physiological saline solution, transferring the resulting cell suspension in the chamber, embedding
intraperitoneally the chamber into an adult rat, feeding the rat in the usual way for four weeks, and harvesting the multiplied human lymphoblastoid cells (human cell density, about 8 x 106 cells per ml). The control cells were treated similarly as described above. The hPTH production was only about 3 y9 per ml cell suspension.
EXAMPLE 6
A human leukemic lymphoblastoid line JBL into which the ability of the human lung carcinoma cells to produce hPTH had been introduced in a manner similar to that described in Example 1 was implanted in the allantoic cavities of embryonated eggs which had been preincubated at 370C for five days. After further incubation of the eggs at this temperature for an additional one week, the chamber was removed.
The multiplied human lymphoblastoid cells thus obtained were treated similarly as described in
Example 1 to produce hPTH. The hPTH production was about 700 ng per ml cell suspension.
In a control experiment in which the human lung carcinoma cells were implanted in the allantoic cavities of embryonated eggs, no cell multiplication was observed.
Claims (12)
1. A process for the production of human parathyroid hormone (hPTH), which process comprises multiplying human lymphoblastoid cells capable of producing said hormone by transplanting said cells to a non-human warmblooded animal body, and allowing the multiplied human lymphoblastoid cells to release said hormone; or multiplying human lymphoblastoid cells capable of producing said hormone by allowing said cells to multiply within a device in which the nutrient body fluid of a non-human warm-blooded animal is supplied to said cells, and allowing the multiplied human lymphoblastoid cells to release said hormone.
2. A process according to Claim 1, wherein the human lymphoblastoid cells are hybridoma cells obtained by cell fusion of a human lymphoblastoid line with human cells capable of producing hPTH.
3. A process according to Claim 2, wherein the hybridoma cells are those obtained by cell fusion of a human lymphoblastoid line with human parathyroid tumor cells.
4. A process according to Claim 2, wherein the hybridoma cells are those obtained by cell fusion of a human lymphoblastoic; line with human kidney tumor cells.
5. A process according to Claim 2, wherein the hybridoma cells are those obtained by cell fusion of a human lymphoblastoid line with human ovarian tumor cells.
6. A process according to Claim 2, wherein the hybridoma cells are those obtained by cell fusion of a human lymphoblastoid line with human lung carcinoma cells.
7. A process according to any one of Claims 2 to 6 wherein the human lymphoblastoid line is a human leukemic lymphoblastoid line.
8. A process according to any one of Claims 2 to 7, wherein the human lymphoblastoid line is
Namalwa, BALL-1, NALL-1, TALL-1 or JBL.
9. A process according to any one of the preceding Claims, wherein the multiplied human lymphoblastoid cells are allowed to release hPTH in the presence of one or more of glycine, leucine, lysine, arginine, cysteine; sodium chloride, potassium chloride, calcium chloride, magnesium sulfate; dopamine, isoproterenol, epinephrine and norepinephrine.
10. A process according to any one of the preceding claims, wherein the non-human warmblooded animal is a chicken, pigeon, dog, cat, monkey, goat, pig, cow, horse, guinea pig, rat, hamster, mouse or nude mouse.
11. A process according to Claim 1 substantially as hereinbefore described in any one of the Examples.
12. Human parathyroid hormone whenever prepared by a process as claimed in any one of the preceding claims.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP55187011A JPS5825439B2 (en) | 1980-12-30 | 1980-12-30 | Method for producing human parathyroid hormone |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2092596A true GB2092596A (en) | 1982-08-18 |
GB2092596B GB2092596B (en) | 1984-05-10 |
Family
ID=16198634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8138588A Expired GB2092596B (en) | 1980-12-30 | 1981-12-22 | Process for the production of human parathyroid hormone |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPS5825439B2 (en) |
KR (1) | KR860001562B1 (en) |
CH (1) | CH652748A5 (en) |
FR (1) | FR2497102A1 (en) |
GB (1) | GB2092596B (en) |
IT (1) | IT1172188B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0251107A2 (en) * | 1986-06-24 | 1988-01-07 | Merrell Dow Pharmaceuticals Inc. | Improved fusion products |
US5010010A (en) * | 1986-10-22 | 1991-04-23 | Selmer-Sande, A.S. | Production of human parathyroid hormone from microorganisms |
WO1992001058A1 (en) * | 1990-07-12 | 1992-01-23 | Ks Biomedix Ltd. | Hybridomas |
US5420242A (en) * | 1986-10-22 | 1995-05-30 | Kaare M. Gautvik | Production of human parathyroid hormone from microorganisms |
US6962796B1 (en) | 1986-10-22 | 2005-11-08 | Nps Allelix Corp. | Production of human parathyroid hormone from microorganisms |
US7018982B2 (en) | 1997-06-19 | 2006-03-28 | Nps Allelix Corp. | Methods useful in the treatment of bone resorption diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA783261B (en) * | 1977-06-15 | 1979-06-27 | Wistar Inst | Method of producing antibodies |
GB2016015B (en) * | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
JPS5562024A (en) * | 1978-10-31 | 1980-05-10 | Hayashibara Takeshi | Preventive and remedy for interferon-sensitive disease |
JPS5598118A (en) * | 1979-01-18 | 1980-07-25 | Hayashibara Takeshi | Preparation of type-2 interferon and drug containing the same |
-
1980
- 1980-12-30 JP JP55187011A patent/JPS5825439B2/en not_active Expired
-
1981
- 1981-12-22 CH CH8192/81A patent/CH652748A5/en not_active IP Right Cessation
- 1981-12-22 IT IT49979/81A patent/IT1172188B/en active
- 1981-12-22 GB GB8138588A patent/GB2092596B/en not_active Expired
- 1981-12-24 KR KR1019810005127A patent/KR860001562B1/en active
- 1981-12-28 FR FR8124270A patent/FR2497102A1/en active Granted
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0251107A2 (en) * | 1986-06-24 | 1988-01-07 | Merrell Dow Pharmaceuticals Inc. | Improved fusion products |
EP0251107A3 (en) * | 1986-06-24 | 1989-10-04 | Merrell Dow Pharmaceuticals Inc. | Improved fusion products |
US5010010A (en) * | 1986-10-22 | 1991-04-23 | Selmer-Sande, A.S. | Production of human parathyroid hormone from microorganisms |
US5420242A (en) * | 1986-10-22 | 1995-05-30 | Kaare M. Gautvik | Production of human parathyroid hormone from microorganisms |
US6146852A (en) * | 1986-10-22 | 2000-11-14 | Nps Allelix Corp. | Production of human parathyroid hormone from microorganisms |
US6962796B1 (en) | 1986-10-22 | 2005-11-08 | Nps Allelix Corp. | Production of human parathyroid hormone from microorganisms |
WO1992001058A1 (en) * | 1990-07-12 | 1992-01-23 | Ks Biomedix Ltd. | Hybridomas |
US7018982B2 (en) | 1997-06-19 | 2006-03-28 | Nps Allelix Corp. | Methods useful in the treatment of bone resorption diseases |
US7507715B2 (en) | 1997-06-19 | 2009-03-24 | Nps Allelix Corp. | Methods useful in the treatment of bone resorption diseases |
US7749543B2 (en) | 1997-06-19 | 2010-07-06 | Nps Pharmaceuticals, Inc. | Methods useful in the treatment of bone resorption diseases |
US8153588B2 (en) | 1997-06-19 | 2012-04-10 | Nps Pharmaceuticals, Inc. | Methods useful in the treatment of bone resorption diseases |
US8765674B2 (en) | 1997-06-19 | 2014-07-01 | Nps Pharmaceuticals, Inc. | Methods useful in the treatment of bone resorption diseases |
Also Published As
Publication number | Publication date |
---|---|
IT1172188B (en) | 1987-06-18 |
CH652748A5 (en) | 1985-11-29 |
JPS5825439B2 (en) | 1983-05-27 |
FR2497102B1 (en) | 1984-11-09 |
JPS57115194A (en) | 1982-07-17 |
FR2497102A1 (en) | 1982-07-02 |
KR860001562B1 (en) | 1986-10-08 |
KR830007085A (en) | 1983-10-14 |
IT8149979A0 (en) | 1981-12-22 |
GB2092596B (en) | 1984-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4377513A (en) | Process for the production of human erythropoietin | |
US4621050A (en) | Process for the production of human colony-stimulating factor | |
US4621052A (en) | Process for the production of human epidermal growth factor | |
US4383034A (en) | Process for the production of human follicle-stimulating hormone | |
US4383035A (en) | Process for the production of human luteinizing hormone | |
US4383036A (en) | Process for the production of human chorionic gonadotropin | |
US4621053A (en) | Process for the production of human peptide hormones | |
US4537852A (en) | Process for the production of human urokinase | |
KR860000894B1 (en) | Producing method of human insulin | |
GB2092596A (en) | Process for the production of human parathyroid hormone | |
GB2083824A (en) | Process for the production of human growth hormone | |
GB2092157A (en) | Process for the production of human calcitonin | |
US4621051A (en) | Process for the production of human multiplication-stimulating activity | |
GB2085891A (en) | Process for the production of human prolactin | |
GB2092156A (en) | Process for the production of human thyroid-stimulating hormone | |
US4624917A (en) | Process for the production of human T-cell growth factor | |
GB2093038A (en) | Process for the production of human placental lactogen | |
GB2091741A (en) | Process for the Production of Human Adrenocorticotropic Hormone | |
JPS6030656B2 (en) | Method for producing human T cell growth factor | |
KR890000383B1 (en) | Process for the production of human t-cell growth factor | |
GB2118560A (en) | Process for producing human Immune Response Suppressor | |
GB2117384A (en) | Production for producing human kallikrein | |
GB2115426A (en) | Process for the production of human T-cell growth factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19921222 |